(Q36192796)

12 August 2017

1 reference

title

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis (English)

1 reference

12 August 2017

1 reference

1 reference

Prabha Ranganathan

1

1 reference

12 August 2017

publication date

1 July 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

481-490

1 reference

Pharmacogenomics: translating functional genomics into rational therapeutics

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Is there a future for TNF promoter polymorphisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Polymorphism of the human TNF-alpha promoter--random variation or functional diversity?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Highly informative typing of the human TNF locus using six adjacent polymorphic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

The role of interleukin-1 in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Tumour necrosis factor 5' promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

An integrated haplotype map of the human major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Dissection of class III major histocompatibility complex haplotypes associated with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.481

21 January 2018

Identifiers

DOI

10.2217/14622416.6.5.481

1 reference

12 August 2017

1 reference